Akt2 expression is associated with good long-term prognosis in oestrogen receptor positive breast cancer

European Journal of Cancer

Volumn 49, Issue 6, 2013, Pages 1196-1204

  Fohlin, Helena ^a,b   Pérez Tenorio, Gizeh ^b   Fornander, Tommy ^c   Skoog, Lambert ^c   Nordenskjöld, Bo ^b   Carstensen, John ^b   Stål, Olle ^b  

^a Regional Cancer Center   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Akt; Breast cancer; Long term; Oestrogen receptor; Prognostic factor; Protein kinase B

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROTEIN KINASE B BETA; TAMOXIFEN;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER TISSUE; DISEASE ASSOCIATION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYMOMA;

ADULT; AGED; BREAST NEOPLASMS; CHEMORADIOTHERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ESTROGEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84875707302     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.12.006     Document Type: Article

References (34)

1. I. Vivanco, and C.L. Sawyers The phosphatidylinositol 3-kinase AKT pathway in human cancer Nat Rev Cancer 2 7 2002 489 501
2. I.G. Maroulakou, W. Oemler, S.P. Naber, and P.N. Tsichlis Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice Cancer Res 67 1 2007 167 177
3. R.L. Dillon, R. Marcotte, and B.T. Hennessy Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression Cancer Res 69 12 2009 5057 5064
4. R.L. Dillon, and W.J. Muller Distinct biological roles for the akt family in mammary tumor progression Cancer Res 70 11 2010 4260 4264
5. W. Liu, J. Bagaitkar, and K. Watabe Roles of AKT signal in breast cancer Front Biosci 12 2007 4011 4019
6. J. Cicenas, P. Urban, and V. Vuaroqueaux Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2 Breast Cancer Res 7 4 2005 R394 R401
7. E. Tokunaga, Y. Kimura, and E. Oki Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients Int J Cancer 118 2 2006 284 289
8. Y. Wu, H. Mohamed, and R. Chillar Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer Breast Cancer Res 10 1 2008 R3
9. M. Spears, C.A. Cunningham, and K.J. Taylor Proximity ligation assays for isoform-specific Akt activation in breast cancer identify activated Akt1 as a driver of progression J Pathol 227 4 2012 481 489
10. O. Stal, G. Perez-Tenorio, and L. Akerberg Akt kinases in breast cancer and the results of adjuvant therapy Breast Cancer Res 5 2 2003 R37 R44
11. T. Kirkegaard, C.J. Witton, and L.M. McGlynn AKT activation predicts outcome in breast cancer patients treated with tamoxifen J Pathol 207 2 2005 139 146
12. S.S. Bacus, D.A. Altomare, and L. Lyass AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival Oncogene 21 22 2002 3532 3540
13. T. van Agthoven, A.M. Sieuwerts, and M.E. Meijer-van Gelder Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance J Clin Oncol 27 4 2009 542 549
14. L.E. Rutqvist, and H. Johansson Long-term follow-up of the Stockholm randomized trials of postoperative radiation therapy versus adjuvant chemotherapy among 'high risk' pre- and postmenopausal breast cancer patients Acta Oncol 45 5 2006 517 527
15. G. Perez-Tenorio, L. Alkhori, and B. Olsson PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer Clin Cancer Res 13 12 2007 3577 3584
16. L.M. McShane, D.G. Altman, and W. Sauerbrei REporting recommendations for tumor MARKer prognostic studies (REMARK) Breast Cancer Res Treat 100 2 2006 229 235
17. G. Tejler, B. Norberg, M. Dufmats, and B. Nordenskjöld Survival after treatment for breast cancer in a geographically defined population Br J Surg 91 2004 1307 1312
18. I. Soerjomataram, M.W. Louwman, J.G. Ribot, J.A. Roukema, and J.W. Coebergh An overview of prognostic factors for long-term survivors of breast cancer Breast Cancer Res Treat 107 3 2008 309 330
19. C. Morelli, M. Lanzino, and C. Garofalo Akt2 inhibition enables the forkhead transcription factor FoxO3a to have a repressive role in estrogen receptor alpha transcriptional activity in breast cancer cells Mol Cell Biol 30 3 2010 857 870
20. S. Guo, and G.E. Sonenshein Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway Mol Cell Biol 24 19 2004 8681 8690
21. G. Perez-Tenorio, and O. Stal Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients Br J Cancer 86 4 2002 540 545
22. S.A. Santi, and H. Lee Ablation of Akt2 induces autophagy through cell cycle arrest, the downregulation of p70S6K, and the deregulation of mitochondria in MDA-MB231 cells PLoS One 6 1 2011 e14614
23. S.X. Tan, Y. Ng, and D.E. James Next generation Akt inhibitors provide greater specificity-effects on glucose metabolism in adipocytes Biochem J. 435 2011 539 544
24. C. Figueroa, S. Tarras, J. Taylor, and A.B. Vojtek Akt2 negatively regulates assembly of the POSH-MLK-JNK signaling complex J Biol Chem 278 48 2003 47922 47927
25. T.R. Lyons, J. Thorburn, and P.W. Ryan Regulation of the pro-apoptotic scaffolding protein POSH by Akt J Biol Chem 282 30 2007 21987 21997
26. G.L. Zhou, D.F. Tucker, and S.S. Bae Opposing roles for Akt1 and Akt2 in Rac/Pak signaling and cell migration J Biol Chem 281 47 2006 36443 36453
27. J. Bostner, M. Ahnstrom Waltersson, and T. Fornander Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer Oncogene 26 49 2007 6997 7005
28. C.C. Ong, A.M. Jubb, and P.M. Haverty Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells Proc Natl Acad Sci U S A 108 17 2011 7177 7182
29. M.M. Caffarel, C. Andradas, and E. Mira Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition Mol Cancer 9 2010 196
30. L.A. deGraffenried, W.E. Friedrichs, and D.H. Russell Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity Clin Cancer Res 10 23 2004 8059 8067
31. J. Luo, B.D. Manning, and L.C. Cantley Targeting the PI3K-Akt pathway in human cancer: rationale and promise Cancer Cell 4 4 2003 257 262
32. J. Baselga, M. Campone, and M. Piccart Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer N Eng J Med. 366 2012 520 529
33. H. Cho, J. Mu, and J.K. Kim Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta) Science 292 5522 2001 1728 1731
34. S. George, J.J. Rochford, and C. Wolfrum A family with severe insulin resistance and diabetes due to a mutation in AKT2 Science 304 5675 2004 1325 1328